Modulation of impact of high fat diet in pathological and physiological left ventricular cardiac hypertrophy by fluvastatin

Biomedicine and Pharmacotherapy

Volumn 64, Issue 3, 2010, Pages 147-153

  Singh, Randhir ^a   Krishan, Pawan ^a  

^a PUNJABI UNIVERSITY   (India)

Author keywords

Cardiac hypertrophy; Fluvastatin; Oxidative stress

Indexed keywords

COLLAGEN; FLUINDOSTATIN; GLUTATHIONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; SUPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; CLINICAL ASSESSMENT; CONTROLLED STUDY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART PROTECTION; HEART WEIGHT; HISTOPATHOLOGY; LIPID DIET; LONG TERM EXPOSURE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN SYNTHESIS INHIBITION; RAT; SWIMMING; WAIST HIP RATIO; WISTAR RAT;

ANIMALS; AORTA, ABDOMINAL; BLOOD GLUCOSE; COLLAGEN; CONSTRICTION; DIETARY FATS; DIETARY SUCROSE; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS, MONOUNSATURATED; GLUTATHIONE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTROPHY, LEFT VENTRICULAR; INDOLES; LIPID PEROXIDATION; LIPIDS; MALE; MUSCLE PROTEINS; OBESITY; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, WISTAR; SUPEROXIDES; SWIMMING; VENTRICULAR REMODELING;

EID: 77649232513     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.06.016     Document Type: Article

References (49)

1. James P.T., Rigby N., and Leach R. International Obesity Task Force. The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 11 (2004) 3-8
2. Alpert M.A. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J Med Sci 321 (2001) 225-236
3. Hubert H.B., Feinleib M., McNamara P.M., and Casteelii W.P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 67 (1983) 968-977
4. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., et al. Obesity and the risk of heart failure. N Engl J Med 347 (2002) 305-313
5. Sadoshima J., and Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol 59 (1997) 551-571
6. Balakumar P., Singh A.P., and Singh M. Rodent models of heart failure. J Pharmacol Toxicol Methods 56 1 (2007) 1-10
7. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
8. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2 (2001) 1712-1719
9. Wolfrum S., Jensen K.S., and Liao J.K. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 23 (2003) 729-736
10. Obayashi M., Yano M., Kohno M., Kobayashi S., Tanigawa T., Hironaka K., et al. Dose-dependent effect of ang II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol Heart Circ Physiol 273 (1997) H1824-1831
11. Balakumar P., and Singh M. The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin Pharmacol Toxicol 99 6 (2006 Dec) 418-424
12. Medeiros A., Oliveira E.M., Gianolla R., Casarini D.E., Negrao C.E., and Brum P.C. Swimming training increases cardiac vagal activity and induces cardiac hypertrophy in rats. Braz J Med Biol Res 37 (2004) 1909-1917
13. Balakumar P., and Singh M. Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats. Pharmacology 78 2 (2006) 91-97
14. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with folin-phenol reagent. J Biol Chem 193 1 (1951) 265-275
15. Simko F., Pelouch V., and Kyselovic J. Captopril fails to reverse hypertrophy of the left ventricle induced by aortic insufficiency in rabbits. Physiol Res 51 1 (2002) 27-33
16. Ohkawa H., Ohishi N., and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95 (1979) 351-358
17. Beutler E., Duron O., and Kelly B.M. Improved method for the determination of blood glutathione. J Lab Clin Med 61 (1963) 882-888
18. Wang H.D., Pagano P.J., Du Y., Cayatte A.J., Quinn M.T., Brecher P., et al. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res 82 7 (1998) 810-818
19. Clayden E.C. Practical section cutting and staining (1971), Churchill Livingstone, London 115
20. Dolber P.C., and Spach M.S. Picrosirius red staining of cardiac muscle following phosphomolybdic acid treatment. Stain Technol 62 (1987) 23-26
21. Mori T., Chen Y.F., Feng J.A., Hayashi T., Oparil S., and Perry G.J. Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. Cardiovasc Res 61 4 (2004) 771-779
22. Alexander J.K. Obesity and the heart. Heart Dis Stroke 2 (1993) 317-321
23. Lauer M.S., Anderson K.M., Kannel W.B., and Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA 266 (1991) 231-236
24. Wong C.Y., O'Moore-Sullivan T., Leano R., Byrne N., Beller E., and Marwick T.H. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 110 (2004) 3081-3087
25. Sjostrom C.D., Lissner L., Wedel H., and Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 7 (1999) 477-484
26. Levy R.J., Troendle A.J., and Fattu M.A. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 87 Suppl. 4 (1993) 1145-1153
27. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319 (1988) 24-33
28. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 (2004) III39-III43
29. Aguila M.B., and Mandarim-de-Lacerda C.A. Heart and blood pressure adaptations in wistar rats fed with different high-fat diets for 18 months. Nutrition 19 (2003) 347-352
30. Woods S.C., Seeley R.J., Rushing P.A., D'Alessio D., and Tso P. A controlled high-fat diet induces an obese syndrome in rats. J Nutr 133 (2003) 1081-1087
31. Ye P., Sheng L., Zhang C., and Liu Y. Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo. J Pharm Sci 9 3 (2006) 365-375
32. Giordano F.J. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115 3 (2005) 500-508
33. Vincent H.K., Powers S.K., Stewart D.S., Demirel H., Shanely A., and Naito H. Obesity and myocardial oxidative stress. Int J Obes Relat Metab Disord 22 (1998) 1-8
34. Desci T., Molnar D., and Koletzko B. Reduced plasma concentrations of alpha-tocopherol and beta-carotene in obese boys. J Pediat 130 (1997) 653-655
35. Ohrvall M., Tengblad S., and Vessby B. Lower tocopherol serum levels in subjects with abdominal adiposity. J Intern Med 234 (1993) 53-60
36. Koneru B., Reddy M.C., Dela Torre A.N., Patel D., Ippolito T., and Ferrante R.J. Studies of warm ischemia in the obese Zucker rat. Transplant 59 (1995) 942-946
37. Luo J.D., and Chen A.F. Perspectives on the cardioprotective effects of statins. Curr Med Chem 10 (2003) 1593-1601
38. Folch J., Lees M., and Stanley G.H.S. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226 (1957) 496-509
39. Engeli S., Negrel R., and Sharma A.M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertenension 35 (2000) 1270-1277
40. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
41. Sicard P., Lauzier B., Oudot A., Busseuil D., Collin B., Duvillard L., et al. A treatment with rosuvastatin induced a reduction of arterial pressure and a decrease of oxidative stress in spontaneously hypertensive rats. Arch Mal Coeur Vaiss 98 (2005) 804-808
42. Brilla C.G., and Weber K.T. Reactive and reparative myocardial fibrosis in arterial hypertension in the rats. Cardiovasc Res 26 (1992) 671-677
43. Assayag P., Carre F., Chevalier B., Delcayre C., Mansier P., and Swynghedauw B. Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype I fibrosis. Cardiovasc Res 34 (1997) 439-444
44. Haider A.W., Larson M.G., Benjamin E.J., and Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32 (1998) 1454-1459
45. Suzumura K., Yasuhara M., and Narita H. Superoxide anion scavenging properties of fluvastatin and its metabolites. Chem Pharm Bull (Tokyo) 47 (1999) 1477-1480
46. Aoki S., Ikeda K., Yamamura M., and Kojo S. Protective effect of fluvastatin on degradation of apolipoprotein B by a radical reaction in human plasma. Biol Pharm Bull 24 (2001) 123-126
47. Rikitake Y., Kawashima S., Takeshita S., Yamashita T., Azumi H., Yasuhara M., et al. Anti-oxidative properties of fluvastatin, an HMGCoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154 (2001) 87-96
48. Bandoh T., Mitani H., Niihashi M., Kusumi Y., Kimura M., Ishikawa J., et al. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol 35 (2000) 136-144
49. Nakamura K., Kusano K., Nakamura Y., Kakishita M., Ohta K., Nagase S., et al. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 105 (2002) 2867-2871